Traws Pharma Completes Enrollment In Ongoing 90-Patient, Open-Label Phase 2 Study Of Ratutrelvir, Investigational Oral, Ritonavir-Free Mpro/3CL Protease Inhibitor, Versus PAXLOVID, In COVID-19 Patients

Ongoing clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID® with fewer adverse events, no viral rebounds to date and faster time to sustained symptom resolution; results recapitulated in PAXLOVID®-ineligible patients, representing a significant population with few effective treatment options

Compressed tablets of tivoxavir marboxil predicted to provide 28-day protection from influenza against wide range of seasonal and pandemic-potential variants

Human influenza prophylaxis challenge study time slot secured for June 2026

NEWTOWN, Pa., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ:TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced the completion of enrollment in its ongoing 90-patient, open-label Phase 2 study of ratutrelvir, an investigational oral, ritonavir-free Mpro/3CL protease inhibitor, versus PAXLOVID®, in patients with mild-to-moderate COVID-19, together with a single arm in PAXLOVID®-ineligible subjects. Patients ineligible to receive PAXLOVID® are frequently at elevated risk for severe disease and require suitable, safe and effective treatment options. Ratutrelvir has the potential to address this gap in care and may be a valuable therapeutic option. The Company also provided an update on the progress of the tivoxavir marboxil program for influenza.